Prospective Pilot Study Assessing Imaging Performance of 89Zirconium-labelled Girentuximab (89Zr-TLX250) PET-CT in Patients With HepatoCellular Carcinoma, IntraHepatic CholangioCarcinoma or Gastro-Entero-Pancreatic Neuroendocrine Neoplasms
Latest Information Update: 21 May 2025
At a glance
- Drugs Girentuximab Zr-89 (Primary)
- Indications Cholangiocarcinoma; Gastro-enteropancreatic neuroendocrine tumour; Liver cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Acronyms ELEGANCE
Most Recent Events
- 21 May 2025 New trial record